- Titre
- P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
- Créateurs - sans rôle
- Martin Hutchings - RigshospitaletCarmelo Carlo-Stella - Humanitas UniversityFranck Morschhauser - Hôpital Claude HuriezMichael Dickinson - The University of MelbourneEmmanuel Bachy - Hôpital Lyon SudGuillaume Cartron - CHU de Montpellier, Montpellier, FranceCyrus Khan - Allegheny Health NetworkMonica Tani - Ospedale Santa Maria delle Croci, Ravenna, ItalyJoaquín Martinez-Lopez - Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, 28041 Madrid, SpainNancy L. Bartlett - Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United StatesAntonio Salar - Department of Hematology, Hospital del Mar, Passeig Maritim, 08003 Barcelona, SpainJoshua Brody - Tisch Cancer Institute, New York, NY, United StatesSirpa Leppa - University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandPauline Baumlin - F. Hoffmann-La Roche Ltd, Basel, SwitzerlandLinda Lundberg - F. Hoffmann-La Roche Ltd, Basel, SwitzerlandJames Relf - Roche Products Ltd, Welwyn Garden City, United KingdomYuying Xie - F. Hoffmann-La Roche Ltd, Mississauga, CanadaAlessia Bottos - F. Hoffmann-La Roche Ltd, Basel, SwitzerlandKathryn Humphrey - Roche Products Ltd, Welwyn Garden City, United KingdomLorenzo Falchi - Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Détails de publication
- HemaSphere, Vol.7(Suppl), pp.e458981a-n/a
- Éditeur
- Lippincott Williams & Wilkins
- Identifiants
- 99139773709311
- Unité académique
- Institut de Génétique Moléculaire de Montpellier - IGMM
- Langue
- English
- Type de ressource
- Journal article
Article de revue
P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
HemaSphere, Vol.7(Suppl), pp.e458981a-n/a
08/08/2023
Indicateurs
1 Consultations de la notice